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Long-term survival after onset of blast crisis in 
chronic granulocytic leukemia 
Case report and therapeutic considerations 
Ellis J. Van Slyck, MD* and Ahmad Samhouri, M D * * 
Current analysis indicates a median sur-
vival of 3.6 months In 356 cases of chronic 
granulocytic leukemia after onset of blast 
transformation. Thirty-five (10.0%) complete 
remissions (CR), all of short duration, were 
observed. Closer scrutiny of the reported 
clinical experience offers clues for improv-
ing this poor outlook. A 76% CR rate can be 
extracted from this total experience by Iden-
tifying cases treated with cytoslne ara-
blnoside combined with one or more other 
agents. In Isolated reports, weekly vin-
cristine and prednisone have yielded good 
remission rates. Two general morphologic 
types of blasts can be distinguished by 
cytochemical stains and other features: lym-
phoid and nonlymphoid (myeloid, 
monocytoid). 
We suggest that the lymphoid type of blast 
crisis Is more responsive to vincristine-pred-
nisone, whereas combination chem-
otherapy, containing cytoslne arabinoside, is 
more effective in nonlymphoid crises. 
We report a blast crisis In which two CRs 
occurred. The patient survived 19 months 
after onset, possibly because he also re-
ceived BCC. 
* Division of Hematology 
** Division of Oncology 
Address reprint requests to Dr. Van Slyck at Divi-
sion of Hematology, Henry Ford Hospital, 2799 
West Grand Blvd, Detroit Ml 48202 
D ESPITE striking improvement in the com-
plete remission rates in both the lymphocytic 
and nonlymphocytic acute leukemias dur-
ing the past decade, the management of 
patients with blast crisis of chronic gran-
ulocytic leukemia (CGL) has remained dis-
couragingly unchanged. Therapeut ic 
regimes, which have a 60% complete remis-
sion rate in acute granulocytic leukemia, 
apparently can produce only short-lived 
complete remissions in about 10% of pa-
tients with blast crisis. However, recent at-
tention to morphologic features of the blast 
cells seen in blastic transformation of CGL 
and renewed interest in cytochemical stain-
ing methods, attended by some surprisingly 
good results in a few clinical experiences,^"^ 
may suggest a rational approach to more 
effective treatment. 
Our recent experience with a patient who 
obtained a gratifying response to treatment 
of his blast crisis demonstrates some of the 
points we wish to make. 
Case Report 
A 62-year-old man with mild diabetes was 
found to have typical Philadelphia chromosome-
positive CGL with hepatosplenomegaly in Febru-
ary, 1973. His initial white blood cell count was 52 
X 10'/liter. The leukocyte alkaline phosphatase 
score was 4. Excel lent control (WBC 10 x lO' / liter) 
was accomplished with brief courses of intermit-
tent myleran in doses no larger than 4 mgs/day 
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On May 3 1 , 1974 the wh i te b lood count 
abruptly rose to 25 x 10'/l iter with 30% my-
eloblasts. Concomitantly the bone marrow was 
hypercellular with 50% blasts. Treatment with 
vincristine 2 mg single IV injection, cytoslne 
arabinoside 200 mgs/day for 10 days, and pred-
nisone 120 mgs daily for 5 days (10 day OAP) 
produced severe bone-marrow hypoplasia with 
associated complications of sepsis and gastroin-
testinal hemorrhage. However, with the recovery 
of marrow cellularity the patient reached com-
plete remission status by July 18, 48 days after 
treatment of the blast crisis had been started. 
Philadelphiachromosome was still demonstrated. 
This remission was maintained with monthly 
cytoslne arabinoside, vincristine and prednisone 
(5 day OAP), and intermittent BCG scarification. 
Blast crisis again supervened on February 10, 
1975, after a seven-month remission. This crisis 
was resistant to intensification of OAP treatment, 
but after treatment in early March with adriamycin 
75 m g / m ^ given twice 14 days apart, a complete 
remission status was recaptured in early Apri l . This 
remission, maintained with 6-mercaptopurine 
and methotrexate orally lasted until October 20, 
1975 (6.5 months). During this interval a transient 
BLAST CRISIS OF CHRONIC 
Complete Remission and 
episodeofasymptomaticcholestatic jaundice was 
related to 6-mercaptopurine toxicity. Subsequent 
responses to adriamycin were only partial and 
brief. The patient died on December 10,1975 from 
sepsis, 19 months after the onset of blast transfor-
mation of CGL. 
C o m m e n t 
This case is no tewor thy on t w o counts, 
one o f w h i c h may be related to the other : 1) 
the length o f remissions was unusual ly long 
and the survival dura t ion was exceeded by 
on l y one other report f ound in the l i terature;" 
and 2) the pat ient received immuno the rapy 
in the fo rm of BCG scar i f icat ion du r i ng his 
f i r s t c o m p l e t e r e m i s s i o n . T h i s a d j u v a n t 
therapy has n o w had widespread use in the 
acute leukemias, but as yet, not in blast crisis 
of CGL. In retrospect and in l ight o f current 
know ledge , this pat ient 's blast crisis should 
have been character ized by add i t iona l study 
(v ide Infra). The good response to the par-
GRANULOCYTIC LfUKEMIA 
Median Survival Data 
No. Median 
of Complete Survival 
Yr. Source Pts. Remission (in mos.) 
69 Hayes, Ellison' 
Foley* 
24 4 
69 13 2 3 
71 Canellos^ 30 6 4 
73 Resegotti ^ 7 1 4 
73 Marmont ^ 24 9 -
73 Monfardini® 70 0 1 
74 Spiers' 50 6 -
74 Vallejos^o 39 4 3.3 
74 Levin " 14 0 -
74 SWOG '2 21 0 -
75 Duhamel 45 3 3 
76 Peterson 19 0 2 
TOTAL 356 35 (10.0%) 2.9 
Figure 1 
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ticular therapy given suggests that the blast 
crisis was myeloid. 
Discussion 
Review of 356 cases of blast crisis (Figure 
1) from 13 different sources in this country 
and Europe^'^'^"^" shows a complete remis-
sion rate of 10% with a median survival of 
only 2.9 months. However, by identifying a 
subset of patients who were treated with 
regimes that included cytoslne arabinoside 
(perhaps the most effective single agent in 
nonlymphocytic leukemias) in combination 
with other drugs, one obtains a complete 
remission rate of 16% (Figure 2). This im-
proved response rate suggests that, as a 
general mode of therapy in blast crisis, 
cytoslne arabinoside combined with one or 
more other antileukemic drugs, is superior to 
regimes that do not include cytoslne ara-
binoside or use it only as a single agent. In 
fact, the 15 complete remissions in 91 cases 
treated with Ara-C combinations compared 
with the 20 complete remissions in 265 
cases treated with other regimes yields a 
highly significant p value of 0.026 that favors 
the former (see Appendix). 
BLAST CRISIS OF CHRONIC GRANULOCYTIC LEUKEMIA 
DATA ON CASES TREATED WITH COMBINATION 
CHEMOTHERAPY CONTAINING Ara C 
Yr. Source 
No. 
Pts. Rx 
Complete 
Remission 
69 Hayes 24 AraC+BCNU 4 
73 Resegotti 7 TRAP 1 
74 Spiers 14 TRAMPCO (L) 4 
74 Vallejos 24 COAP 
DOAP, OAP 3 
75 Duhamel 22 AraC+Pred. 3 
TOTAL 91 15 (16%) 
A. AraC = Cytosine Arabinoside; P, Pred. = prednisone 
BCNU = 1,3 Bis (2 chloroethyl) 1-nitrosourea 
T = Thioguanlne; R, D = Daunorubicin; M = Methotrexate 
C = cyclophosphamide; 0 = Oncovin; L = L-asparaginase 
Figure 2 
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On the other hand, Canellos et al, ' Mar-
mont,^ and Howes and Emerson^ have re-
p o r t e d e x c e l l e n t resu l ts ( c o m b i n e d 
complete remission rate of 29%) using only 
vincristine and prednisone. Other investiga-
tors have been unable to duplicate these 
results, which suggests that there may exist a 
subpopulation of blast crisis patients whose 
disease is sensitive to these latter agents, 
similar to most lymphoid leukemias in this 
respect. It is therefore pertinent that Mathe et 
ap5 had noted in 1967 that the morphology 
of the blasts in patients undergoing transfor-
mation from CGL had lymphoid characteris-
tics in most cases. Boggs''' theorized that 
during the aggressive or acute leukemic 
phase, a clone of pluripotential stem cells 
expands and dominates the morphologic 
picture. These cells may take on characteris-
tics of lymphoid, myeloid, or monocytoid 
differentiation to a greater or lesser extent. 
Subsequently, Beard et aP' described seven 
cases of acute leukemia, six lymphocytic 
and one undifferentiated, in whom the Phila-
delphia chromosome was demonstrated, 
with pseudo-Pelger-Huet and hypogranular 
characteristics present in the circulating 
granulocytes. Two of the seven cases de-
veloped a CGL-like picture while in remis-
sion from the acute leukemia, but five did 
not. Beard and his investigators postulated 
that al I these cases represent a blast crisis of 
CGL, with suppression of the usual chronic 
phase. Marmont and Damasio^ noted that 
hypogranular blasts were present in the pa-
tients who had the best response in their 
series. Howes and Emerson^ described a 
patient whose blast cells morphologically 
appeared lymphoid and in wh i ch the 
cytoplasm showed positivity with the peri-
odic acid Schiff (PAS) stain. This patient 
obtained a prompt and prolonged remission 
initiated by high doses of vincristine and 
prednisone alone. 
Further evidence favoring the lymphoid 
origin of the occasional blast crisis comes 
from the recent recognition of the enzyme, 
terminal deoxynucleotidyl transferase, in the 
blast cells of several cases of blast crisis of 
18,19 -[-pijj enzyme is normally found in 
lymphoid cells of thymic origin and has also 
been identified in leukemic cells from 12 of 
14 cases of acute lymphoblastic leukemia, 
but not in leukocytes from other types of 
leukemia. 
A recent review^" of the clinical charac-
teristics of 67 cases of blast crisis of CGL 
subdivided the blast cell line as follows: 38 
mye lob las t ic , 21 lymphoblast ic , 7 
erythroblastic, and one unique blast cell 
type. 
MORPHOLOGY OF BLASTS IN BLASTIC TRANSFORMATION 
High N:C 
Dark Blue Cytoplasm 
Blue Grey Cytoplasm 
Coarse Granules 
Fine Granules 
Auer Rods 
LYMPHOID 
+ 
+ 
MYELOID 
± 
± 
± 
-I-
MONOCYTOID 
-I-
+ 
N : C = nuclear cytoplasmic ratio 
Figure 3 
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Morphology and Cytochemical 
Staining 
Shaw et al^' stressed the heterogeneity of 
the morphological and cytochemical fea-
turesofthe blasts in eight cases of blast crisis 
of CGL, but Hammouda et a \ " found lym-
phoid staining behavior in their four cases. 
Peterson, Bloomfield, and Brunning'" were 
able to divide their cases into those with 
lymphoid characteristics and those with 
non lympho id characterist ics. The mor-
phologic features, which help in this dif-
f e r e n t i a t i o n , i n c l u d e : the nuc l ea r 
cytoplasmic ratio; the presence of coarse 
cytoplasmic granulation, as opposed to fine 
or absent granulation; the staining character 
of the cytoplasm with ordinary hematologic 
stains; and the presence of Auer rods (Figure 
3). There has been an upsurge in interest in 
cy tochemica l staining as an addi t ional 
means of making distinctions between the 
types of blasts. Admittedly, there are some 
blast cells whose behavior to cytochemical 
stains is ambiguous or heterogonous, but 
some cases clearly show blast cells which 
stain w i t h l ympho id characterist ics, al-
though these are probably in the minority. 
Figure 4 reviews the most useful stains for 
this purpose. Peroxidase and Sudan Black 
positivity in the myeloid type of blasts is 
helpful, whereas Oi l Red O stains lymphoid 
but not myeloid cells. The particulate block-
like positivity to PAS in the lymphoid type of 
cell is quite characteristic, provided it per-
sists after diastase digestion for 30 minutes. 
Finer PAS positive granules have less specif-
icity and for that reason less significance. 
Specific and nonspecific esterase stains may 
be difficult to interpret until one develops 
experience with them, but they may be 
helpfully confirmatory for the other stains. 
Unequivocal nonspecific esterase positivity 
identifies blast cells of monocyte origin. 
CYTOCHEMICAL STAINS IN BLAST CRISIS OF CGL 
LYMPHOID 
Peroxidase 
Sudan Black 
Oil Red 0 
PAS* 
Specific Esterase*" 
Non-sp'fic est'ase* 
-F 
+ 1 
V 
MYELOID 
-f 
-F 
V 
-F 
V 
MONOCYTOID 
V 
V 
V 
V 
V 
-F 
* PAS = PER IODIC ACID-Schiff; **Specific Esterase=Naphthol 
AS-D Chloroacetate esterase; ***Non-sp'fic est'ase=Alpha 
Naphthol Butyrate method; +1 = Blxl< - like particulate 
positivity; V = variable reaction. 
Figure 4 
303 
Van Slyck and Samhouri 
Cytogenetics 
Although Rowley" has recently stressed 
that in acute granulocytic leukemia patients 
who demonstrate no chromosomal abnor-
malities in their blasts have a therapeutic 
advantage over patients who do show ab-
normalities, the situation is not so clear in the 
blast crisis of CGL. With few exceptions, all 
of these blast-crisis patients have a Phila-
delphiachromosome present and the major-
ity of them have an additional chromosomal 
abnormality A double Philadelphia chro-
mosome is sometimes observed. An extra 
chromosome 8 and abnormalities of chro-
mosome 17 occur less frequently, but as a 
rule the further changes are heterogeneous 
with no useful prognostic pattern as yet 
identified. A possible exception to this last 
statement may be found in the observation of 
Canellos et aV-^" that better results were 
obtained with vincristine-prednisone in pa-
tients with hypodiploidy in their blast kar-
yotypes. These investigators did not 
correlate the presence of hypodiploidy with 
the possible lymphoid character of blasts as 
determined by other morpholog ic and 
cytochemical staining features. In the future 
this correlation should be made in analyses 
of data. 
Our experience with the management of 
blast transformation identifies other features 
which seem to predict a favorable result. 
One of these, as in the case reported here, is 
the abruptness of the transformation. This 
generally correlates with the percentage of 
blasts appearing in the marrow, the total 
marrow cellularity, and the lack of marrow 
fibrosis. Contrariwise, a gradual increase in 
the aggressiveness of the chronic leukemia 
combined with a slowly increasing percent-
age of blasts would seem to imply a poor 
prognosis, as does increased marrow fibrosis 
demonstrated by bone marrow biopsy. 
Plan for Therapy 
Both the foregoing data and our own 
experience encourage us to propose the 
following strategy for therapy of blast crisis. 
which, although admittedly speculative, 
might improve the rate of complete remis-
sion and the length of survival: 
1. The presence of blast crisis should be 
established by means of the following fac-
tors: marrow blasts greater than 30%, rising 
leukocyte alkal ine phosphatase (LAP), 
cytogenetic aneuploidy, and associated 
clinical changes. 
2. The predominant number of the blasts 
should be segregated into either lymphoid or 
nonlymphoid (i.e., myeloid, myelomonocy-
tic, monocytoid, erythroblastic, etc.) cell 
types. This step wi l l require the use of the 
morphological and cytochemical methods 
described above. 
3. Patients with lymphoid blasts should be 
treated w i th high dose intravenous v in -
cristine and oral prednisone. Nonlymphoid 
(myeloid) crises should be managed with 
cytosine arabinoside combined with one or 
more other agents, such as thioguanlne," 
cyclophosphamide," adriamycin," vin-
cristine, and prednisone. 
4. We would suggest that those patients in 
whom cytogenetic analysis indicates hypo-
diploidy be included in the lymphoid group 
and receive vincristine-prednisone alone as 
initial therapy, but we realize that this data 
may not be available when the decision to 
start treatment must be made. 
5. Lastly, we have been encouraged by the 
reports of SokaP'-" and Gutterman et aP° on 
the favorable responses in chronic and acute 
granulocytic leukemia with BCG scarifica-
tion during maintenance of the remission 
state. We also are tempted to believe that the 
BCG administered to our patient may have 
favorably influenced the length of his remis-
sion. If subsequent experience substantiates 
the value of immunotherapy in this clinical 
setting, we further suggest that it be consid-
ered as adjuvant therapy in patients who 
attain complete remission. 
While one can hardly expect to attain 
remission rates and survival durations com-
parable to those for acute granulocytic leu-
304 
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kemia, we feel nonetheless that significant 
improvement w i l l result from fo l l ow ing 
these guidelines. 
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Appendix 
Two by Two con t ingency table for de te rm in ing x 2 value for Ara-C c o m b i n a t i o n t reatment 
compared ei ther to no t reatment or to s ingle-drug treatment. 
TREATMENT REMISSIONS FAILURES TOTAL 
Observed Expected Observed Expected 
Ara-C combin. 15 8.95 76 82.05 91 
None or One 20 26.05 245 238.95 265 
TOTAL 35 321 356 
(adjusted) 
(15-8.95-0.5)^ 
8.95 
(deviation-0.5)^ 
expectat ion 
(26.05-20-0.5)^ 
26.05 
(82.05-76-0.5)^ 
82.05 
(245-238.95-0.5)^ = 5.13 
238.95 
x2 = 3 . 8 4 1 ^ p = 0.05 
x2 = 5 . 4 1 2 ^ p = 0.02 
x^ = 5.13 ^ p ( interpolated) = 0.026 
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